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Background: The B-subunit of Shiga toxin (STxB) specifically binds to the glycosphingolipid Gb3 that is highly
expressed on a number of human tumors and has been shown to target tumor cells in mouse models and ex vivo
on primary colon carcinoma specimen.
Methods: Using a novel ex vivo STxB labeling (ESL) method we studied Gb3 expression in cytological specimens
of primary human breast tumors from 107 patients, and in synchronous lymph node metastases from 20 patients.
Fluorescent STxB was incubated with fine-needle aspiration (FNA) specimens, and Gb3 expression was evaluated by
fluorescence microscopy. Furthermore, 11 patient-derived human breast cancer xenografts (HBCx) were evaluated
for expression of Gb3 by ESL and FACS. In addition, the biodistribution of fluorescent STxB conjugate was studied
after intravenous injection in a Gb3 positive HBCx model.
Results: Gb3 expression was detected in 62 of 107 patients (57.9%), mainly in epithelial tumor cells. Gb3 positivity
correlated with estrogen receptor expression (p ≤ 0.01), whereas absence of Gb3 expression in primary tumors was
correlated with the presence of lymph node metastases (p ≤ 0.03). 65% of lymph node metastases were Gb3
positive and in 40% of tested patients, we observed a statistically significant increase of metastatic Gb3 expression
(p ≤ 0.04). Using concordant ESL and flow cytometry analysis, 6 out of 11 HBCx samples were scored positive.
Intravenous injections of fluorescent STxB into HBC xenografted mice showed preferential STxB accumulation in
epithelial cells and cells with endothelial morphology of the tumor.
Conclusion: The enhanced expression of Gb3 in primary breast carcinomas and its lymph node metastases indicate
that the development of STxB-based therapeutic strategies is of interest in this pathology. Gb3 expressing HBCx can
be used as a model for preclinical studies with STxB conjugates. Finally, the ESL technique on FNA represents a
rapid and cost effective method for the stratification of patients in future clinical trials.
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Breast cancer is the most common malignancy affecting
women in the Western world. Besides surgery, radiation,
chemotherapy, and endocrine treatment, immunother-
apy has become an established part of systemic therapy
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been shown to be effective as first- or second-line ther-
apy in the management of metastatic disease with plat-
inum derivates and anthracyclines being the most active
compounds [2]. These often have substantial side effects,
however, and the identification of new agents for highly
specific targeted therapy is an important area of cancer
research. Bacterial toxins such as adenylate cyclase,
botulinum, cholera, and Shiga-like toxins (verotoxins)
might be used to establish novel therapeutics against
tumor malignancies, either as independent anti-neoplasticl Ltd. This is an Open Access article distributed under the terms of the Creative
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Their capacity to target specific signaling pathways might
reduce side-effects [3].
Shiga and Shiga-like toxins are produced by Shigella
dysenteriae and enterohemorrhagic strains of Escherichia
coli. These toxins are composed of two non-covalently
attached parts: the enzymatically active A-subunit, and
the non-toxic, pentameric B-subunit (STxB) [4]. STxB
specifically binds to the sugar moiety of the glycosphin-
golipid globotriaosylceramide (known as CD77, Gb3,
and ceramide trihexoside) in the plasma membrane of
target cells, and mediates uptake and intracellular trans-
port of the toxin [5,6]. Shiga toxin is internalized by
clathrin-independent endocytosis [7], and is then trans-
ported to the endoplasmic retriculum following the
retrograde route [8]. The A-subunit is cleaved in the
trans-Golgi network, and the enzymatically active A1
part is translocated from the lumen of the endoplasmic
reticulum to the cytosol. The A1 fragment irreversibly
modifies ribosomal 28S RNA, leading to the inhibition
of protein biosynthesis and cell death by apoptosis [5].
Deregulation of Gb3 expression has been described in
different human and animal malignancies [9]. Further-
more, increased expression of Gb3 was reported for sev-
eral solid tumors such as breast [10], ovarian [11],
pancreatic [12,13] and colon [13,14] cancers, and malig-
nant meningioma [15]. Tumor-associated Gb3 is access-
ible to natural ligands (i.e. Shiga-like toxins), making
them candidates for oncological applications [5]. The
anti-neoplasic activity of Shiga toxin has been docu-
mented in xenograft models of astrocytoma, renal cancer
and malignant meningioma [15-18]. However, the use of
holotoxin in humans might be problematic since the ac-
tion of the catalytic A-subunit is not tumor cell specific
and is likely to cause kidney damage. In contrast, STxB
might be developed into a delivery tool for therapeutic
entities that by themselves have some tumor specificity.
Further development of STxB-based targeted therapies
of human breast cancer requires exact knowledge about
Gb3 expression in primary tumors and lymph node me-
tastases. Furthermore, the development of rapid and cost
effective diagnosis methods is essential for the appropri-
ate choice of pre-clinical models and for the stratifica-
tion of patients in future clinical trials. The purpose of
this study was to evaluate the expression of Gb3 in the
cytological specimens of primary and metastatic human
breast carcinoma, as well as in HBCx, using a novel
ex vivo STxB labeling (ESL) technique.
Here, we report that the majority of breast cancer pa-
tients express Gb3 in primary tumors, and increase Gb3
expression in lymph node metastases in 40% of the
cases. Furthermore, a novel ESL technique was devel-
oped as a useful tool for the detection of Gb3 expression
in tumor cells. Finally, STxB conjugate accumulates inGb3 positive HBCx after intravenous injection, indicat-
ing that STxB-based therapeutic strategies might be of
interest in this pathology.
Methods
Breast cancer patients
All used human cytological or histological samples were re-
siduals of specimens sampled during conventional medical
consultation. The Institutional Review Board of Institute
Curie approved the study. The Institutional approval was
elaborated according to Helsinki's Declaration of human
rights. Human breast cancer specimens were obtained fol-
lowing informed consent from all patients undergoing
cytological or histological examination.
Tumor specimens were collected between January
2009 and January 2012 from 87 patients with previously
untreated primary breast carcinomas. Furthermore, 20 pa-
tients with previously untreated breast carcinomas associ-
ated to clinically palpable axillar lymph node metastases
were available for this study. Clinicopathological patient
data (i.e. size of primary tumor, location, lymph node
extension) were recorded. Additional samples, including
20 samples of invasive breast carcinoma, 12 samples of
mammary adenofibroma, 14 samples of normal breast
tissue, and 7 healthy kidney samples were available for
Gb3 extraction.
Primary lesions and lymph node metastases were fine-
needle sampled. For diagnosis, a large part of aspirated
material was smeared onto slides and stained according
to the May-Grünwald-Giemsa (MGG) method. The
remainder of the cytological material was placed in
Dulbecco's Modified Eagle Medium (DMEM) without
supplements for the ex vivo STxB labeling (ESL) pro-
cedure. Immediately after aspiration, a histological
biopsy was also performed after local anesthesia. Patients
were treated by neoadjuvant chemotherapy according to
the Institute’s guidelines, and finally underwent surgery
at the primary site with axillary lymph node cleaning.
Biopsies from primary lesions were immediately fixed and
stained with hematoxylin-eosin-safran. Histological sec-
tions were evaluated according to Elston-Ellis histological
grading including a mitotic count on 10 high power fields.
Estrogen and progesterone receptors as well as HER2
expression were evaluated using a set of monoclonal
antibodies: ER (clone 6F11; 1/200; Novocastra, Rungis,
France), PR (clone 1A6; 1/200; Novocastra), and HER2
(clone CB11; 1/1,000; Novocastra). Proliferation index
was assessed using monoclonal anti-Ki67 antibody (Ki67,
clone MIB-1; 1/75; DAKO, France). All primary tumors
were classified according St. Gallen International Expert
Consensus of 2011 [19]. This classification distinguishes
following categories: Luminal A (ER and/or PR positive,
HER2 negative and Ki67 low), Luminal B/HER2- (ER and/
or PR positive, HER2 negative and Ki67 high), Luminal B/
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(ER and PR negative, HER2 positive), Triple Negative (ER,
PR, HER2 negative).
Patient-derived human breast cancer xenograft model
Tumor specimens were obtained from breast cancer pa-
tients and established as xenografts, as previously de-
scribed [20]. Briefly, fresh tumor fragments were grafted
subcutaneously into the interscapular fat pad of female
Swiss nude mice under anesthesia. Mice were kept in
specific pathogen-free animal housing at Institut Curie,
and received estrogen (17 mg/mL) diluted in drinking
water. HBCx appeared at the graft site two months after
grafting. These were subsequently transplanted from
mouse to mouse. The experimental protocol and animal
housing were in accordance with institutional guidelines
as proposed by the French Ethics Committee (Agreement
B75-05-18). 11 HBCx established from different patients
were available for cytological and flow cytometry analysis
using STxB-Cy3 and STxB-Alexa Fluor® 488 conjugates,
respectively. The recombinant mutant STxB-Cys was
produced in our laboratory as previously described [21]
(see below). Fine-needle aspiration followed by ESL was
performed after the xenografts reached 10 to 12 mm of
diameter. The animals were sacrificed, xenograft were re-
moved and placed in sterile DMEM solution at 4°C till
flow cytometry analysis. Furthermore, ER, PR and HER2
status of all HBCx was evaluated by immunohistochemis-
try under the same conditions as described above.
Purification of STxB
Recombinant STxB was purified from bacteria as previ-
ously described [21]. Briefly, bacterial extracts were
loaded on a Q Sepharose High Performance strong
anion exchange column (GE Healthcare) and eluted in a
linear NaCl gradient (25 mM Bis-Tris–HCl, pH 6). STxB
eluted from the column at around 150–250 mM, and
was dialyzed against coupling buffer (20 mM HEPES-
KOH, pH 7.4, 150 mM NaCl), and subjected to coupling
with Cy3 (cyanine 3; Amersham Biosciences) or Alexa
488 (AlexaFluor® 488, Life Technologies) fluorochromes
according to the supplier's instructions. Cy3- and Alexa
488-coupled STxB were purified by PD-10 column (GE
Healthcare), snap frozen and stored at −80°C.
Ex vivo STxB Labeling (ESL) method
This technique was applied to the fine needle aspirates
obtained from patients and from xenografted mice. One
part of aspirated material was smeared on slides and
stained according to the May-Grünwald-Giemsa method
for estimation of cellularity. Another part was placed in
Dulbecco's Modified Eagle Medium (DMEM) for ESL.
The isolation of cancer cells required centrifugation
through a density gradient. 3 ml of cell suspension waslayered onto a sterile aqueous medium containing ficoll
and sodium diatrizoate at a predetermined density
of 1.199 and 1.077 g/ml at 25°C. Centrifugation at
1800 rpm for 20 min at room temperature resulted in
the separation of epithelial and white blood cells that ac-
cumulated at the interface of the two ficoll fractions,
from red blood cells that passed through the interface
and formed a pellet at the bottom of the tube. The can-
cer cell-fraction was collected and washed with sterile
DMEM to remove contaminating separation medium.
After the last centrifugation step cells were suspended in
1 ml of DMEM containing 1 μM of STxB-Cy3, and incu-
bated for 1 hour at 25°C with slow agitation. After two
wash steps in phosphate buffered saline, 150 μl of cell
suspension was projected onto slides by centrifugation
at 500 rpm for 8 min using a Shandon CytoSpin 2 Cyto-
centrifuge. Slides were air dried, and nuclei labeled with
DAPI. To confirm the epithelial nature of extracted cells,
labeling with anti-AE1/AE3 antibody (Dako, polyclonal,
rabbit anti human, 1/200) was performed. Samples were
observed by epifluorescence microscopy and evaluated
for the presence of STxB-Cy3 labeling. Samples were
judged suitable for this study when at least 100 cells with
epithelial morphology were counted on the slide. Pa-
tients with lower cell count were excluded from the
study. Cell density and morphology were judged on
MGG stained slides and on ESL slides using DAPI nu-
clear staining.
Gb3 extraction from normal tissue, breast cancer
specimens and HBCx
Tumors and healthy breast tissues as well as breast cancer
xenografts were frozen in liquid nitrogen immediately
after surgery, and stored at −80°C. Tissues were weighed
and mechanically homogenized in 1 mL of water. Gb3
expression was quantified after lipid extraction, STxB
overlay, and immunodetection as previously described
[22]. Briefly, lipids were extracted using chlorophorm/
methanol (1:2), followed by drying of the chloroform
phase, and saponification of lipids at 56°C for 1 hour in
1 ml of methanol/KOH. The isolated neutral glycolipids
were separated on high-performance thin-layer chroma-
tography (TLC) plates (Merck, Darmstadt, Germany), and
visualized by incubation with STxB (20 nM) and subse-
quent immunolabeling.
Flow cytometry of breast cancer xenografts
Single-cell suspensions were prepared from excised tu-
mors as previously described [23]. Briefly, tumors were
removed from sacrificed mice, minced and incubated
twice in non-enzymatic dissociation buffer (Invitrogen)
followed by mild enzyme digestion step including collage-
nase III (200 U/ml; Sigma-Aldrich, St Louis, MO, USA),
DNase I (200 U/ml; Sigma-Aldrich), each incubation for
Figure 1 Gb3 expression in normal breast tissue, adenofibroma,
breast carcinoma and normal human kidney specimens.
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filtered through a 40 μm nylon mesh cell strainer (BD Bio-
sciences, San Diego, CA, USA), and released cells were
centrifuged at 1200 rpm for 2 min, separated using a
double Ficoll gradient (Histopaque; Sigma-Aldrich; dens-
ities 1.077 and 1.119), washed in PBS, and stored at 4°C
until staining and flow cytometry. Immunostaining was
performed on all HBCx using Alexa Fluor® 488 labeled
STxB (1 μM), mouse anti human EpCAM_PerCP-Cy5.5
(Biolegend), and rat anti mouse pan-H2_PE (Biolegend).
Dissociated cells were incubated with antibody mix for
20 min at 4°C in the dark, and after washing, 2 ng/ml
40,60-diamidino-2-phenylindole (DAPI) (Invitrogen) was
added. Data were acquired on a standard LSRII (BD
Biosciences) with 488 nm laser excitation. ‘Fluores-
cence minus one’ (FMO) controls were used to estab-
lish negative cut-offs.
Live (negative for DAPI staining) single (by eliminating
doublets in FSC-W/FSC-A scattergramms) human cells
(EpCAM pos and panH-2 neg) were analyzed and re-
sults were calculated in ratio mean fluorescence intensity
(MFI test/MFI FMO). Cell populations with ratio strictly
over 1.5 were considered as positive for Gb3 expression.
Data analysis was performed using the Flowjo software
(Tree Star, Ashland, OR, USA).
Intravenous injection of STxB-Cy3
To study the biodistribution of STxB-Cy3 conjugates
in vivo, five mice were xenografted with the Gb3 ex-
pressing breast cancer HBCx-174, and injected with
STxB-Cy3 (100 μg/20 g) in the retro-orbital sinus. Ani-
mals were sacrificed after 24 hours. One half of the
xenograft was placed in DMEM for future FACS ana-
lysis, whereas another half as well as kidney, liver, spleen,
lung, small and large intestine were sampled and fixed in
4% of PFA. Paraffin embedded sections were labeled
with DAPI and evaluated by epifuorescence microscopy.
Statistical analysis
Correlations between Gb3 expression and other variables
were analyzed using Pearson's chi-square test. Addition-
ally, Wilcoxon Signed Rank Test was carried out to
compare the expression in primary tumor and lymph
node metastases for each patient. Furthermore, one-way
ANOVA was used to compare Gb3 expression in normal
breast tissue, adenofibroma and breast carcinoma. The
level of significance for rejection of the null hypothesis of
no relationship between variables was taken to be p ≤ 0.05.
Results
Gb3 expression is increased in human breast carcinoma
compared to normal tissue
In order to evaluate global quantity of Gb3 in normal and
tumor breast tissue, Gb3 was extracted and quantifiedusing a previously published STxB overlay method [22]
Normal breast tissue expressed Gb3 in the range from
13.0 to 53.0 ng per mg of tissue (mean 24.52 ng/mg),
whereas breast carcinoma showed 1.5 times higher Gb3
expression (mean 37.9 ng/mg) with a higher range from
8.0 ng/mg to 121.0 ng/mg. However, this difference was
not significant (p > 0.5). In contrast to breast carcinoma,
adenofibroma showed comparable Gb3 levels to normal
tissue (mean 28.51 ng/mg, min. 1.8 ng/mg, max. 45.0 ng/
mg). In addition, normal kidney tissue, known for high
Gb3 levels, was extracted as a positive control. This tissue
showed mean values of 85.72 ng of Gb3 per mg of tissue
(min. 31.5 ng/mg, max. 124.7 ng/mg), which was 2.3 times
higher than the mean of Gb3 in breast carcinoma. These
data are summarized in Figure 1.
Gb3 positivity correlates with estrogen receptor
expression in primary human breast cancer
Fine-needle aspiration (FNA) is a standard cytological
tool for diagnostics of suspected primary or secondary
malignancies [24]. In order to evaluate Gb3 expression
on epithelial cancer cells, we developed a novel tech-
nique for the ex vivo STxB labeling (ESL) in which live
cells from dissociated tumors are incubated with STxB
prior to microscopical viewing (see Methods section).
We combined the FNA and ESL techniques on cyto-
logical specimens of primary breast cancers of 107
patients. Roughly 100 to 500 cells with epithelial
morphology per patient were subjected to ESL. Cell
density and morphology were judged on MGG stained
slides and on ESL slides using DAPI nuclear stain. Ex-
amined patients were separated in two groups accord-
ing to Gb3 expression in primary tumors. 62 patients
(57.9%) expressed Gb3 in primary tumor (Gb3 positive
group). Regarding the receptor status of Gb3 positive
patients, 48/62 (77.4%) were positive for estrogen
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(PR), and 40/62 (64.5%) for HER2. 5/62 (8.1%) were
triple negative (Table 1). Using Pearson’s chi-squared
test, Gb3 expression was significantly correlated to
estrogen receptor expression (p ≤ 0.01; Figure 2A),
whereas no correlation was found with age, histo-
logical type, grade, molecular classification, mitotic
index, progesterone receptor or HER2 expression. Fur-
thermore, no significant relationship was found be-
tween Gb3 positivity and the presence of lymph node
metastases. 33 of 62 Gb3 positive patients (53.2%) had
lymphatic extension, whereas 29/62 patients (46.8%)
had no lymph node metastases.
Absence of Gb3 expression (Gb3 negative group) was
observed in 45 patients (42.1%). Gb3 negativity wasTable 1 Gb3 expression and clinicopathological
characteristics of primary breast carcinomas























Luminal A 6 7
Luminal B 42 16
Luminal B/HER2 + 31 15
Luminal B/HER2 - 11 1
HER2 positive 9 9
Triple Negative 5 10
Not classified 0 3
*Median of mitotic index and grade; **Mean.significantly correlated (p ≤ 0.03) with higher number of
lymph node metastases in this group (Figure 2B); in-
cluding 34/45 lymph node positive (75.6%) and 11/45
lymph node negative (24.4%) patients. No correlation
was found in this group with age, histological type,
grade, molecular classification, mitotic index, estrogen
and progesterone receptor or HER2 expression.
In conclusion, Gb3 is expressed in the majority of pri-
mary breast carcinomas. Gb3 positivity correlates with
estrogen receptor expression in primary breast cancer,
whereas absence of Gb3 is linked to frequency of lymph
node metastases.
Gb3 expression is enhanced in lymph node metastases
compared to the primary tumor in 40% of patients
Several receptors, including ER, PR and HER2 show dis-
cordant expression between primary tumor and lymph
node metastases [25]. In order to assess Gb3 expression
in primary and metastatic cancer we selected 20 patients
with previously untreated breast carcinomas associated
to clinical palpable pathological lymph nodes. Primary
breast tumors and synchronous lymph node metastases
were fine-needle sampled and examined by the ESL
method. Gb3 expression was estimated in epithelial
appearing cells using the following scale: low (<25% of
labeled cells), moderate (25 - 50% of labeled cells) and
high (>50% of labeled cells). Gb3 expression in primary
breast tumors and lymph node metastases is summa-
rized in Figure 2C. No expression was seen in 10 pri-
mary tumors and 7 metastases. Gb3 was expressed in 10
(50%) primary tumors, including low expression in 5,
moderate in 4, and high in 1 patient. Furthermore 13
(65%) metastases showed STxB-Cy3 accumulation. This
included low Gb3 expression in 3, moderate in 7, and
high in 3 patients.
We observed differences regarding the individual re-
ceptor expression between primary tumor and its lymph
node metastases. 8 patients (40%) showed an increase of
the relative Gb3 expression in lymph node metastases
compared to primary tumor. This group included 5 pa-
tients showing no expression in primary tumor and low
(2 patients) or moderate (3 patients) expression in lymph
node metastases. Further two patients presented low
number of positive cells in primary tumor and moderate
(1 patient) or high (1 patient) expression in metastases.
The remaining patient increased tumor Gb3 expression
from moderate in mammary mass to high in axillary me-
tastases. On the other hand, 10% (2 patients) showed a
decreased expression from low level in primary tumor to
no expression in nodal metastases. 10 patients (50%) had
no change in the Gb3 expression, including 5 patients
with no expression, 3 patients with moderate and 2
patients with low or high respective expression in both
specimens (Figure 2D). Overall statistical analysis of
Figure 2 Gb3 expression in primary breast tumors and lymph node metastases. A: Estrogen receptor and Gb3 expression in primary breast
tumors. Note: Gb3 positivity (Gb3 + group) is correlated with estrogen receptor expression. **: p ≤ 0.01, ER: estrogen receptor. B: Presence of
axillary lymph node metastases in patients with and without Gb3 expression in primary breast cancer. Note a higher number of patients with
lymph node metastases in the Gb3 negative group. *: p ≤ 0.03, LN: lymph node. C: Relative numbers of Gb3 expressing cells. D: Change in Gb3
expression between primary and metastatic tumors. Note: 40% of patients showed relative increase, whereas 50% had no change, and 10% lost
Gb3 expression in the lymph node metastases compared to the primary tumor.
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metastases using Wilcoxon Signed Rank Test showed a
significant increase in Gb3 expression in lymph node
metastases in studied patients (p ≤ 0.04).
Our results show that Gb3 is expressed in 65% of
lymph node metastases. Furthermore, 40% of patients
showed an increase of the relative number of STxB posi-
tive cells between primary tumor and metastases.
Gb3 is mainly expressed on tumor epithelial cells in FNA
of primary and secondary breast cancers
In order to assess which cells express Gb3 in FNA of pri-
mary and secondary mammary cancers we used standard
cytochemical MGG labeling as well as combined immuno-
cytochemistry and ESL techniques. Roughly 100 to 500
cells with epithelial morphology were subjected to STxB
accumulation. Patients with lower cell count were ex-
cluded from the study. Cell density and morphology was
judged on MGG stained slides and on ESL slides using
DAPI nuclear stain. The epithelial nature of STxB-positive
cells was confirmed using immunocytochemical stain-
ing for pan-cytokeratins, showing a cytoplasmic co-
localization of STxB-Cy3 and AE1/AE3 signals (Figure 3A).
As shown in Figure 3A, D and E, labeling by STxB was no-
ticed mainly in epithelial cells (i.e. larger epithelial tumor
cells forming lobular, tubular and/or acinic structures).Isolated malignant cells were usually less positive than
clustered cells (Figure 3B and C). The STxB signal was
distributed mainly in the perinuclear region, or diffusely
throughout cytoplasm, showing fine granular appearance.
Furthermore, STxB staining was less frequently observed
in neutrophils and rare in macrophages. Here, the signal
was mostly cytoplasmic and appeared coarse granular.
Structures with capillary morphology, which were some-
times seen, were strongly positive for STxB labeling
(Figure 3F).
These results confirm that tumor epithelial cells are
the major Gb3 expressing cell type in FNA of primary
and metastatic breast cancer.
Gb3 positive HBCx can be selected by ESL
Breast cancer xenografts are useful tools for preclinical
assessment of new treatments because of their similar
molecular profile to the corresponding patient tumors
[26]. Recent studies with these and similar breast cancer
xenografts completed in our institution show that hu-
man breast cancer xenografts maintain the overall
histologic, genomic and gene expression profile of the
corresponding patient tumors and remains stable
throughout sequential in vivo generations [20,27]. ESL
and FACS used for the evaluation of Gb3 expression
in 11 HBCx. Concordant results between ESL and
Figure 3 Gb3 expression in fine-needle aspirates of human primary breast cancers and lymph node metastases. A, B, C, F: Fine-needle
aspirates from different patients. A: Tubular structure with Gb3 (red) expression within the cytokeratin expressing epithelial cells (green); B: isolated
cytokeratin expressing epithelial cells (green) with no Gb3 expression; C: low number of Gb3 (red) expressing individualized epithelial cells (green);
F: Gb3 (red) expression in cells with endothelial morphology forming a capillary-like structure (center). D, E: Gb3 expression (red) in lobular structures of
a primary tumor (D), and in tubular formations in lymph node metastases of the same patient (E). Note similar morphological appearance, i.e. cohesive,
polygonal cells forming lobular structures in both specimens. Bars: 20 μm.
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positive, and 5 negative (Table 2). Furthermore, using
flow cytometry it was found that 4 out of 6 positive
HBCx had two different tumor cell populations with
high or low Gb3 expression levels. As illustrated in
Figure 4A, Gb3 expressing cells were mainly morpho-
logically well differentiated (i.e. cohesive polygonal
epithelial cells forming lobular structures) and showed
granular, often perinuclear intracytoplasmic labeling.
Furthermore, less differentiated cells (i.e. groups of
cells without particular formation) less frequently ac-
cumulated STxB (Figure 4B). In addition, 8 HBCx
were available for Gb3 extraction. ESL and Gb3 ex-
traction showed concordant results in 6 from 8 tested
HBCx, including 4 positive and 2 negative xenografts.
2 HBCx were positive in Gb3 extraction and negative
in ESL (Table 2). ER, PR and HER2 status was studied
in all xenografts and the results are summarized in
Table 2. Tested panel of HBCx included 1 ER+/PR-/
HER2- and 2 HER2+ xenografts as well as 8 triple
negative HBCx. There were no correlation between
ER, PR or HER2 status and Gb3 expression.These results show that Gb3 is expressed in epithelial
cells of HBCx, and that ESL is useful for the selection of
Gb3 positive grafts for future pre-clinical trials.
Gb3 positive tumor cells can be targeted by STxB
conjugate after intravenous injection
In order to study its biodistribution in mice and the pos-
sibility to target Gb3 positive tumors, STxB-Cy3 conju-
gate was injected intravenously. STxB accumulation was
studied on fixed tumor and organ specimens by fluores-
cence microscopy. Gb3 expression (revealed through
STxB accumulation) was observed in several organs, in-
cluding kidney, liver, intestine, and in HBCx. In xeno-
grafts, fluorescent signal was observed in tumor cells
with epithelial morphology as illustrated in Figure 4E.
However, the labeling was heterogeneous in its intensity
with uneven intratumoral distribution, including tumor
lobules with and without staining. The majority of
STxB-positive cells were localized in the periphery of the
tumor lobules, whereas central, often necrotic areas
were devoid of the staining. Regarding tumor stroma,
Gb3 expression was noticed in the majority of cells with
Table 2 ER, PR, HER2 and Gb3 expression in HBCx
id IHC ESL FACS Gb3 extraction
ER PR HER2 Gb3 n count n pop % min fluo Ratio MFI % max fluo Ratio MFI ng Gb3/mg of tissue
BC11 - - - - 31499 1 100 1.5 x x N.A.
BC138 - - - + 10579 2 85 1.2 15 13.1 2.7
BC143 - - - - 9704 1 100 1.1 x x 0.0
BC147 - - - + 9051 2 85.6 2.9 14.7 22.9 45.7
BC151 - - + - 2032 1 100 1.0 x x 0.0
BC152 - - - - 8444 1 100 1.0 x x 15.0
BC162 - - - + 25850 1 100 5.8 x x N.A.
BC174 - - - + 26528 2 23.7 2.9 76.3 30.1 29.0
BC389 - - + + 27074 1 100 2.6 x x N.A.
BC52 + - - + 20355 2 67.4 3.8 32.6 29.7 200.0
BC73 - - - - 20583 1 100 1.2 x x 5.9
+: positive; −: negative; n count: number of counted cells; n pop: number of present cell populations; % min fluo: percentage of cells expressing low or no Gb3
expression; % max fluo: percentage of cells with higher Gb3 expression. N.A.: data not available.
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cells showed no staining (Figure 4E). Gb3 expression
was observed in a variety of organs. Most intense label-
ing was seen in the kidney, notably in ducts of the me-
dulla (Figure 4C), and with lower intensity in cortical
tubules. Glomerular tufts showed low labeling. Further-
more, STxB labeling of low intensity was observed in
cells with endothelial morphology of liver (Figure 4D)
and in rare epithelial cells of intestinal villa. Lung, spleen
and intestine were otherwise STxB negative.
These results demonstrate the possibility of targeting
Gb3 expressing HBCx after an intravenous injection,
using STxB conjugates. However, non-tumor tissue, not-
ably renal medulla, also shows strong STxB binding.
Discussion
In the present study, we evaluated Gb3 expression in
primary and metastatic human breast carcinomas. Using
a novel ex vivo STxB labeling (ESL) technique on fine-
needle aspirates we observed two groups of primary
breast carcinomas (Gb3 positive and Gb3 negative tu-
mors) with different clinicopathological behavior.
There are few reports about Gb3 expression in pri-
mary breast cancer [10,28]. In agreement with a previous
study [10], we observed Gb3 expression on the majority
of cytological specimens. Gb3 positivity was not corre-
lated with the majority of clinical data, including age,
histological type, grade, and mitotic index. We observed
a correlation between Gb3 and estrogen receptor expres-
sion, which was different from previous data [10]. This
apparent disagreement might be due to a low patient
number (25 patients) in the previous publication. Several
studies reported an increase of Gb3 expression in malig-
nant tumors compared to adenomas or normal tissue
[12-14]. Our data on total Gb3 expression levels (usingan extraction method) showed that overall Gb3 levels
were 1.5 times higher in breast carcinoma versus healthy
breast tissue. These results did not reach the significance
level, probably because of the low patient number.
The link between Gb3 expression and clinical behavior
is still very little explored. Cell differentiation appears to
be one of the relevant aspects. Indeed, in pancreatic and
ovarian carcinomas a higher level of Gb3 expression was
noticed in less differentiated tissue [13,29]. In agreement
with these studies we observed Gb3 expression on cells
with malignant cytological characteristics: large tumor
cells forming lobular and tubular structures. However,
Gb3 was expressed on cohesive epithelial cells and to
lower proportion in individualized tumor cells. This ob-
servation may indicate that a certain degree of differenti-
ation is needed for Gb3 expression. Supporting this
hypothesis, our data show that Gb3 positivity is corre-
lated to estrogen receptor expression. It has been shown
that well differentiated human breast carcinomas express
higher levels of estrogen receptor [30]. Decrease or loss
of Gb3 expression might be associated with malignant
behavior as shown for other glycosphingolipids in breast
cancer, including GD3, GT3, GQ1bα [31]. Furthermore,
reduction of Gb3 was observed in breast cancer cell
cultures and was associated with cancer stem cells
[32]. However, the clinical relevance of decreased Gb3
expression remains to be addressed. Taken together,
Gb3 expression was correlated with estrogen receptor
expression and higher morphological cell differenti-
ation, whereas Gb3 negative primary breast tumors
were morphologically lower differentiated and showed
a statistical link to higher number of lymph node me-
tastases. Our observations indicate that Gb3 positive
carcinomas may present lower malignant behavior
compared to Gb3 negative tumors.
Figure 4 Gb3 expression in mice with HBCx. Upper part: STxB-Cy3 accumulation in tumor and organs after ESL or intravenous injection. A, B: Gb3
expression in fine-needle aspirates of HBCx with accumulation of STxB-Cy3 in tubular structures (A), or individualized cells (B). C: Diffuse and high
expression of Gb3 in tubular structures of renal medulla, D: Diffuse and low expression in liver parenchyma in cells with endothelial morphology lining liver
sinusoids, E: Gb3 expression in HBCx. Note a diffuse and high STxB-Cy3 accumulation in tumor cells with epithelial morphology compared to the absence
of Gb3 expressing cells in tumor stroma (*). Lower part: FACS analysis of Gb3 expressing tumor cells in different HBCx. Note the lack of Gb3 positivity in
HBCx-11 (left), the presence of two populations of Gb3 expressing cells in HBCx-52 (middle), and of one Gb3 positive population in HBCx-162 (right).
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primary breast tumors and synchronous lymph node
metastases. Half of the patients showed a change in Gb3
expression, including 40% of studied patients with an in-
crease of the relative number of Gb3 expressing cells in
metastatic lesions and 10% with decreased expression.
Several molecules, including HER2, estrogen and proges-
terone receptors, show heterogeneous expression be-
tween primary tumor and metastases [33]. ER and PR
variation is different depending on study and it can
reach 7.5% to 35% and 16% to 48.6% for ER and PR re-
spectively. HER2 expression was shown to be more
stable with variations between 2.9% to 24% (reviewed in
[33]). The causes and mechanisms leading to increase ordecrease of these molecules on cancer cells are still un-
clear. However, several mechanisms were proposed, in-
cluding cellular differentiation level (i.e. migrating
cancer stem cells and epithelial-mesenchymal transition)
and accumulation of genetic and epigenetic events dur-
ing cancer progression [33]. It is probable that similar
mechanisms, particularly related to cell differentiation,
are implicated in Gb3 expression changes between pri-
mary breast cancers and lymph node metastases. Fur-
thermore, we speculate that Gb3 has different functions
in both tissue contexts, possibly depending interacting
partners. The same molecule could thereby be linked to
apparently opposing phenotypes, i.e. a decrease of Gb3
expression with increased metastatic spread in primary
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lial tumor cell differentiation in metastatic tissue. This
hypothesis is expected to stimulate further research
into the molecular mechanisms of glycosphingolipid
functions, for which even the most basic aspects are
still unexplored.
Discordant expression of molecular markers or target
molecules between primary breast cancer and synchron-
ous lymph node metastases is an important issue that
can have a significant impact on clinical outcome of the
disease and on the choice of appropriate therapy [34].
In the case of STxB-based therapy, enhanced Gb3 ex-
pression in primary tumor and metastases might lead
to greater therapeutic benefit in patients with highest
overall Gb3 expression. Thus, the development of a
simple and efficient method for the evaluation of Gb3
expression was needed. For this, we developed the ESL
technique for estimation of Gb3 expression on low
quantities of freshly obtained tumor cells. It can be ap-
plied during routine clinical intervention (i.e. fine-
needle aspiration) before chemotherapy or radiation
treatment. The heterogeneity of Gb3 expression in
breast carcinoma and the relatively low number of
epithelial cells that are obtained by one needle pass
(ca. 50–100 epithelial cells) might be a limitation of
this technique [10], and may require repeated fine-
needle aspiration. Other techniques like immunohisto-
chemistry, mass spectrometry, thin layer chromatog-
raphy, or flow cytometry can be used to quantify Gb3
expression [4,14,35]. However these techniques often
need expensive equipment, special knowledge, and large
amounts of tissue or cells [4].
Increased Gb3 expression in breast cancer and its
lymph node metastases indicates that the development
of STxB-based therapeutic strategies is of interest in this
pathology. STxB-based drugs can target malignant epi-
thelial cells and tumor vasculature as shown for colon
and pancreatic cancers [12,17]. Furthermore, Johansson
and colleagues [36] showed recently that cisplatin in-
duced Gb3 expression in malignant mesothelioma cells.
Many chemotherapeutic regimens involved in breast
cancer treatment include platinum derivatives [37], how-
ever the major problem with cisplatin treatment is the
development of acquired-drug resistance of the cancer
cells [38]. Thus STxB conjugates could be used as sec-
ond line therapy in treatment of cisplatin resistant breast
cancers.
Conclusion
Despite clinical improvements, major problems are still
associated with breast cancer treatment. The development
of targeted therapies that effectively eliminate cancer cells
with minimal effects on healthy tissue is a major objective
in clinical cancer research. The enhanced expression ofGb3 in primary breast carcinoma and their lymph node
metastases, as described here, is a favorable condition for
the development of STxB-based therapeutic strategies.
Furthermore, the newly described ESL technique on fine-
needle cytological specimens represents a rapid and cost
effective method to determine the Gb3 status of patients
prior to making a therapeutic choice.
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